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In this issue of Cell Stem Cell, Zheng et al. (2011) report that HSCs expressing PD-L1 display enhanced
engraftment in irradiated allogeneic recipients. Independently in Nature, Fujisaki et al. (2011) observe
allogeneic HSCs persisting in proximity to regulatory T cells in nonirradiated recipients, further connecting
HSCs and immune tolerance.Allogeneic transplantation of HSCs is
apotential therapy for a number of nonma-
lignant or malignant disorders for which
the replacement of diseased HSCs with
new ones that possess normal myeloid
and lymphoid reconstitution potential is
desirable. Allogeneic HSC engraftment
can be achieved across major donor-
host genetic disparities using potent con-
ditioning regimens, but at the cost of (1)
high treatment-related mortality due to
graft-versus-host-disease (GVHD), a con-
dition caused by donor-derived T lym-
phocytes, and (2) infections, which are
precipitated by the immunosuppressive
treatments needed to treat GVHD and
prevent graft rejection. Transplantation
using reduced intensity conditioning and
T cell depleted grafts is better tolerated,
but the balance between engraftment
and rejection continues to pose a signifi-
cant challenge (reviewed in Welniak
et al., 2007).
In murine models, purified HSCs (which
lack the potential to induce GVHD) can
establish long-term hematopoietic chime-
rism, but only in conjunction with signifi-
cant host conditioning. Even when using
total body irradiation, substantially larger
doses (10- to 60-fold greater) of alloge-
neic HSCs are needed to achieve radio-
protection and hematopoietic reconstitu-
tion in comparison with syngeneic HSCs
(Shizuru et al., 1996). In addition, Reisner
and colleagues demonstrated in 1995
that the HSC dose required to induce
chimerism further increases as the irra-
diation dose decreases (Welniak et al.,
2007). In this issue of Cell Stem Cell,
Zheng et al. (2011) generated HSCs
with increased allogeneic engraftment
ability. They compared the engraftmentpotential of LinSca-1+Kit+CD34Flk2
bone marrow cells cultured 8 days in
a previously defined serum-free medium
to that of ex vivo purified HSCs isolated
from C57BL/6 donors and infused in
lethally irradiated BALB/c recipients.
Based on limiting dilution studies in the
presence of admixed syngeneic compet-
itor cells, they calculated that ex vivo
expanded HSCs contained 11 times
more engrafting cells than the original
input cell number, but engrafted 40-fold
better than their purified noncultured
counterparts, as determined by hemato-
poietic reconstitution of different blood
lineages, 16 weeks posttransplant. This
suggested that a factor independent of
the cell number contributed to the persis-
tence of the infused HSCs. Zheng and
colleagues demonstrated that this factor
was an elevated expression of PD-L1, a
T cell inhibitory molecule, by the HSCs
themselves. Only the PD-L1-positive
fraction of HSCs displayed enhanced re-
populating capacity in allogeneic settings.
When the in vitro expanded HSCs were
generated from PD-L1 KO donors, their
engraftment ability was decreased or
abolished, depending on the number of
cells infused, in comparison with that of
wild-type equivalents.
B7-H1/PD-L1 is a transmembrane pro-
tein that belongs to the B7 family of T cell
costimulatory molecules. The binding of
PD-L1 to its receptor PD-1 dampens
T cell activation, reduces IL-2 and IFNg
secretion, decreases proliferation and
cytotoxicity, and induces apoptosis (re-
viewed in Francisco et al., 2010). PD-L1
is expressed by immune cells such as
macrophages, dendritic cells, and T and
B cells, but is also expressed in otherCell Stem Cetissues including endothelial cells and
pancreatic islet cells. Studies in mouse
models demonstrate that the PD-L1/PD-
1 pathway induces T cell exhaustion in
chronic viral diseases but also contributes
to the maintenance of peripheral toler-
ance against self-antigens and to the
protection of tissues from inflammation
during infections (Mueller et al., 2010). In
humans, there is increasing evidence
that some tumor cells express PD-L1,
which serves as an immune escape
mechanism (Dong et al., 2002).
Zheng et al. showed that the cultured
PD-L1-expressing HSCs inhibit the prolif-
eration of allogeneic T cells in vitro,
whereas PD-L1 KO HSCs do not. They
also showed, using immunocompromised
SCID/BALB/c recipients, that T cells, but
not NK cells, were the immune cells tar-
geted by HSC-induced tolerance. The
authors verified that cultured human cord
blood HSCs express PD-L1 and reduce
allogeneic T cell proliferation in mixed
leukocyte cultures.
A recent study investigating the fate of
allogeneic HSCs in nonirradiated immu-
nocompetent mice points to the immune
privilege of HSCs, albeit in a very distinct
fashion, involving the topology of the
HSC niche and its proximity to regulatory
T cells. Fujisaki and colleagues (Fujisaki
et al., 2011) performed allogeneic trans-
plantation of c-kit+Sca+Lin bone marrow
cells from C57BL/6 donors to BALB/c
recipients, without any conditioning, and
followed their persistence in recipients’
bone marrow. Using intravital microscopy
to track single cells, they detected 90%
of the infused enriched HSCs in the
vicinity of the endosteal surface, 1 month
after transplantation, indicating that thell 9, August 5, 2011 ª2011 Elsevier Inc. 87
Cell Stem Cell
Previewstransplanted cells were not rejected by
the recipient’s intact immune system.
The persisting quiescent HSCs did not
contribute to hematopoiesis, but at least
a subset of them maintained long-term
repopulating capacity, as confirmed by
secondary transplantation. The authors
also established that this immune toler-
ance was specific to HSCs, because
coinjected Lin+ bone marrow cells disap-
peared 1 week after infusion. The authors
observed that bonemarrow FoxP3+ Tregs
were localized near the HSC niche and
surrounded infused HSCs in the alloge-
neic transplantation experiments. These
Tregs expressed TGFb and increased
levels of IL-10 following successful
allogeneic HSC seeding. Treg depletion
by either diptheria toxin or anti-CD25
antibody led to near full rejection of the
previously seeded HSCs, which was as-
sociated with a local elevation of TNF-a
and IL-4.
These two studies reveal new facets of
the immunobiology of allogeneic HSC
engraftment. Zheng et al. show engraft-
ment of cultured HSCs overexpressing
PD-L1 in mice in which the medullary
environment has been disrupted by
irradiation, resulting in full hematopoietic
reconstitution. Fujisaki et al. show stable
seeding of allogeneic HSCs in the suben-
dosteal medulla and maintenance of HSC
function without active hematopoietic
activity in nonconditioned recipients. As
different as they are, there are some
points of convergence between the two
reports.
Recently, Sharpe and colleagues dem-
onstrated that PD-L1 inhibits effector
T cell functions but can also convert naive88 Cell Stem Cell 9, August 5, 2011 ª2011 ElCD4 T cells into induced Tregs in the pres-
ence of TGFb (reviewed in Francisco
et al., 2010). IL-10, on the other hand,
has been shown to increase PD-L1
expression by monocytes in another
immunosuppressive milieu, the tumor
microenvironment (Kuang et al., 2009).
The impact of irradiation on medullary
architecture and function is overwhelming
and likely affects all of the above parame-
ters. It is important to note, however, that
radiosensitivity differs between cell types.
Thus, Tregs are relatively more resistant
than other T cell subsets (Nador et al.,
2010), which may favor the regeneration
of an immunoprotective niche soon after
HSC infusion in irradiated recipients. The
relationship between PD-L1 expression
in HSCs and their progeny, Tregs and
the stem cell niche, thus warrants further
exploration, as does their potential inter-
play with mesenchymal stem cells, which
are also immunosuppressive under the
right circumstances (Caplan and Correa,
2011).
The persistence of quiescent allogeneic
HSCs in nonirradiated recipients is in-
triguing, but is per se of no clinical benefit.
Having stealthily taken root within the host
organism, the foreign HSCs would have
to extend tolerance induction to their
progeny in order to productively con-
tribute to hematopoiesis. PD-L1, which
can protect tumors (Dong et al., 2002)
and parenchymal tissues against immune
assaults (Mueller et al., 2010), may find
a role beyond that shown here in incom-
ing HSCs. PD-L1 may perhaps be har-
nessed to afford immunoprotection to
the progeny of HSCs, or the progeny of
other stem cells as well (Zhao et al.,sevier Inc.2011). Interestingly, Zheng et al. found
PD-L1 to be upregulated by cultured
human cord blood CD34+ cells, which
may be exploited in the clinic in the
context of single- or double-cord blood
transplantation, a promising therapeutic
strategy that may be compromised by
insufficient cell dose or immune rejection.REFERENCES
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